Autopsy report · NCT03944707

Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients

“Company decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 9 months before it stopped.
• 76 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Asthma

Interventions

LOU064 100 mg; Placebo

Participants

76

Sites

19

Countries

Argentina, Germany, Poland, Russia, United States

Trials that died the same way

• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (97% match in meaning)
• V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse
  “Company business decision” (92% match in meaning)
• A Phase 2 Extension of Study GCS-100-CS-4003
  “Corporate decision” (90% match in meaning)
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
  “Business Decision” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.